Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting

Schedule of significant expenses


		For the Three Months Ended
		June 30, 2025									June 30, 2024
		Ophthalmic			Corporate &						Ophthalmic			Corporate &
		Technology			Other			Total			Technology			Other			Total

Operating Income
Revenue		$	—		$	—		$	—		$	22,625		$	—		$	22,625
Cost of revenue			—			—			—			(490,361)			—			(490,361)
Gross Profit			—			—			—			(467,736)			—			(467,736)
Operating Expenses
Research and development:
Salaries and benefits			424,032			—			424,032			1,752,197			—			1,752,197
Non-cash stock based compensation expenses			157,291			—			157,291			232,154			—			232,154
Facilities expenses			62,432			—			62,432			278,134			—			278,134
Direct clinical and non-clinical expenses			16,263			—			16,263			722,126			—			722,126
Other expenses			14,560			—			14,560			69,255			—			69,255
Supplies and materials			—			—			—			1,249,597			—			1,249,597
Depreciation expense			—			—			—			293,710			—			293,710
Total research and development			674,578			—			674,578			4,597,173			—			4,597,173

Selling, general, and administrative
Non-cash stock based compensation			326,363			5,190,000			5,516,363			308,902			—			308,902
Professional fees			1,164,039			—			1,164,039			637,619			—			637,619
Salaries and benefits			361,513			10,000			371,513			1,497,747			—			1,497,747
Insurance expense			209,000			—			209,000			210,582			—			210,582
Investor relations			140,948			—			140,948			115,983			—			115,983
Director fees and expense			97,500			—			97,500			101,875			—			101,875
Other expenses			68,275			—			68,275			350,004			—			350,004
Facilities expense			83,263			—			83,263			122,307			—			122,307
Sales and marketing			15,066			—			15,066			263,340			—			263,340
Travel, lodging and meals			10,354			2,383			12,737			150,476			—			150,476
Total selling, general, and administrative			2,476,321			5,202,383			7,678,704			3,758,835			—			3,758,835
Reacquisition of license rights			—			—			—			2,864,600			—			2,864,600
Total Operating Expenses			3,150,899			5,202,383			8,353,282			11,220,608			—			11,220,608
Segment Net Loss			(3,150,899)			(5,202,383)			(8,353,282)			(11,688,344)			—			(11,688,344)
Other (Expense) Income
Other segment income (expense) ⁽¹⁾			(337,637)			—			(337,637)			634,645			—			634,645
Total Other Expense, net			(337,637)			—			(337,637)			634,645			—			634,645
Net Loss		$	(3,488,536)		$	(5,202,383)		$	(8,690,919)		$	(11,053,699)		$	—		$	(11,053,699)


		For the Six Months Ended
		June 30, 2025									June 30, 2024
		Ophthalmic			Corporate &						Ophthalmic			Corporate &
		Technology			Other			Total			Technology			Other			Total
Operating Income
Revenue		$	14,720		$	—		$	14,720		$	27,618		$	—		$	27,618
Cost of revenue			(48)			—			(48)			(693,388)			—			(693,388)
Gross Profit			14,672			—			14,672			(665,770)			—			(665,770)
Operating Expenses															—
Research and development:
Salaries and benefits			844,032			—			844,032			3,757,798			—			3,757,798
Non-cash stock based compensation expenses			221,968			—			221,968			438,740			—			438,740
Facilities expenses			133,269			—			133,269			446,573			—			446,573
Direct clinical and non-clinical expenses			88,920			—			88,920			1,336,305			—			1,336,305
Other expenses			34,302			—			34,302			114,405			—			114,405
Supplies and materials			25,130			—			25,130			2,309,784			—			2,309,784
Depreciation expense			—			—			—			625,169			—			625,169
Total research and development			1,347,621			—			1,347,621			9,028,774			—			9,028,774

Selling, general, and administrative
Non-cash stock based compensation			541,314			5,190,000			5,731,314			648,548			—			648,548
Professional fees			2,173,425			—			2,173,425			1,529,661			—			1,529,661
Salaries and benefits			853,493			10,000			863,493			2,983,915			—			2,983,915
Insurance expense			423,457			—			423,457			429,716			—			429,716
Investor relations			259,635			—			259,635			228,624			—			228,624
Director fees and expense			195,000			—			195,000			213,750			—			213,750
Other expenses			181,482			—			181,482			425,805			—			425,805
Facilities expense			166,419			—			166,419			248,954			—			248,954
Sales and marketing			37,087			—			37,087			449,568			—			449,568
Travel, lodging and meals			17,331			2,383			19,714			237,483			—			237,483
Total selling, general, and administrative			4,848,643			5,202,383			10,051,026			7,396,024			—			7,396,024
Reacquisition of license rights			—			—			—			4,864,600			—			4,864,600
Total Operating Expenses			6,196,264			5,202,383			11,398,647			21,289,398			—			21,289,398
Segment Net Loss			(6,181,592)			—			(11,383,975)			(21,955,168)			—			(21,955,168)
Other (Expense) Income
Other segment income (expense)⁽¹⁾			(790,477)			—			(790,477)			(20,632)			—			(20,632)
Total Other Expense, net			(790,477)			—			(790,477)			(20,632)			—			(20,632)
Net Loss		$	(6,972,069)		$	(5,202,383)		$	(12,174,452)		$	(21,975,800)		$	—		$	(21,975,800)

Schedule of segment assets


		As of
		June 30, 2025									December 31, 2024
		Ophthalmic			Corporate &						Ophthalmic			Corporate &
		Technology			Other			Total			Technology			Other			Total
Segment Assets
Cash		$	7,532,291		$	—		$	7,532,291		$	2,121,463		$	—		$	2,121,463
Digital assets			—			45,500,000			45,500,000			—			—			—
All other assets			2,627,345			—			2,627,345			1,546,296			—			1,546,296
Total Assets		$	10,159,636		$	45,500,000		$	55,659,636		$	3,667,759		$	—		$	3,667,759

⁽¹⁾	Other segment expenses and losses include interest income, interest expense, gain (loss) on extinguishment of debt and change in fair value of equity consideration.